Strep Throat Treatment Market Size

Strep Throat Treatment Market size was over USD 2.18 billion in 2024 and is poised to exceed USD 3.86 billion by 2037, growing at over 4.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of strep throat treatment is evaluated at USD 2.26 billion. The rise in several deaths from rheumatic heart disease mainly in industrial fields will exponentially help the strep throat treatment market to grow in the expected CAGR. Over 288 348 people die from rheumatic heart disease each year, the majority of them reside in low- or middle-income nations. Recurrent strep infections can make some people's immune systems respond negatively to bodily tissues, leading to heart valve inflammation and scarring. This is the condition known as rheumatic fever and this fever can take away lives.

Another reason to propel the strep throat treatment market by the end of 2036 is the increasing prevalence of streptococcus bacteria across the world. Some European nations (the United Kingdom, France, Ireland, the Netherlands, and Sweden) have reported a rise in invasive Group A streptococcal (iGAS) cases among children under the age of ten in 2022, especially since September. In the same time frame, reports of multiple iGAS-related deaths in children under 10 have also been made, notably from France, Ireland, and the UK. The number of pediatric iGAS cases reported in France and the UK has been several times greater than pre-pandemic values for the same time frame. The most frequent cause of bacterial pharyngitis in children of school age is GAS bacteria. Scarlet fever, a fine, red rash, and moderate symptoms such as headache, sore throat, and fever are typically the result of gas infections. The inflammation and scarring of heart valves brought on by rheumatic fever subsequently lead to rheumatic heart disease.